Distributor Name -	Distributor Address -		
Phone Number:	Fax:		

Distributor Email Address:

After Hours Phone Number:

Operation Da	ate:		Instruments /Procedure	Implant Sys Manufactur Orthofix 3451 Plano Lewisville, T www.ortho	red by: Parkway IX 75056		
Surgeon:			Implant Label				
Patient:							
Catalog	Lot#	Item Name		Single Use	QTY	HOSP	HOSP
Number				ltem		IN	OUT

CSSD Count

Date

CONSTRUX® Mini Ti Spacer System

Patient Information Leaflet

Dear Patient,

During your surgery, the devices referenced above from the CONSTRUX[®] Mini Ti Spacer System were implanted in your body. Because of this, you must be aware of the following information.

GENERAL INFORMATION

Name and Model of the device

The CONSTRUX Mini Ti Spacer System is comprised of a variety of implants that have a PEEK core with integrated porous titanium end plates.

What is the device for?

The CONSTRUX[®] Mini Ti Spacer System is indicated for spinal fusion procedures at one or two contiguous levels within the cervical spine (C2-T1) in skeletally mature patients with degenerative disc disease (DDD). CONSTRUX Mini Ti spacers are implanted in the cervical intervertebral disc space and are intended to facilitate vertebral fusion by stabilizing adjacent vertebrae, maintaining disc height and preventing the collapse of one vertebra onto another.

Kind of patient on whom the device is intended to be used

This device is intended to be used in skeletally mature patients with degenerative disc disease (DDD).

Special operating instructions for the use of the device

There are no special operating instructions for the patient.

Intended performance of the device

The CONSTRUX[®] Mini Ti Spacer System is intended to facilitate spinal fusion at one or two contiguous levels within the cervical spine (C2-T1) in skeletally mature patients.

Side Effect

Potential adverse events include, but are not limited to:

- 1. Failure of the device to provide adequate mechanical stability.
- 2. Loss of fixation of the implant.
- 3. Device component failure.
- 4. Migration or bending of the device.
- 5. Loss of bony alignment.
- 6. Non-union.
- 7. Fracture of bony structures.
- 8. Resorption without incorporation of any bone graft utilized.
- 9. Immunogenic response to the implant materials.
- 10. Dysphagia.

Risk that can remain despite preventive measure

Refer to Side Effects.

Warnings about risk that may arise from the use of the device

Postoperative care is important. Be aware of the limitations of the implant and use caution regarding weight bearing and body stress on the device prior to secure bone healing.

Precautions and other measure to be taken by the patent or a health professional

The CONSTRUX[®] Mini Ti Spacer System has not been evaluated for safety and compatibility in the Magnetic Resonance (MR) environment. It has not been tested for heating, migration or image artifact in the MR environment. The safety of CONSTRUX Mini Ti Spacer System in the MR environment is unknown. Scanning a patient who has this device may result in patient injury.

Regular Exams, check and/or care of the device

Routine follow-up after implantation is by the surgeon's decision. Usually, there are visits to check the fusion achieved after surgery. This happens in the first few weeks after surgery. Imaging is commonly done, according to the surgeon's post-operative guidelines. These are done until the time of fusion. Once healed, follow-up checks are done according to the surgeon's decision.

Symptoms that could indicate that the device is not functioning as it should

Some symptoms can indicate that the device is not functioning as it should. These include, among others, lasting pain, device component fracture, loss of fixation, non-union, and fracture of the vertebra, neurological injury, and vascular or visceral injury.

What to do if you suspect that device is malfunction

If you have any of the symptoms described above, contact your primary surgeon. If he/she is not available, contact a trained surgeon. Please seek medical assessment if a surgeon is not available.

Expected lifetime of the device, what influences it, and precautions to take

The implant is intended to remain implanted permanently.

Other cases in which the patient should contact a health professional in relation to the device

Refer to Symptoms that could indicate that the device is not functioning as it should.

Materials and substances included in the device

CONSTRUX[®] Mini Spacer System implants are made of titanium as described by ASTM F67.

Any residues from production that could put the patient at risk

CONSTRUX[®] Mini Spacer implants have been evaluated for the presence of manufacturing residuals that could pose a risk to the patient. These evaluations determined that there are no residual materials present at toxic levels on finished devices. It is known that the production process may introduce residues, contaminants, and additives with potential toxicity. All CONSTRUX[®] Mini Spacer System implants undergo validated cleaning processes at multiple points in the manufacturing process to reduce the presence of residual materials below the level of concern

Important Note:

Please report any serious problem with the Implant System. You must contact Orthofix, and the Therapeutic Goods Administration.

<u>Orthofix</u>

3451 Plano Parkway, Lewisville, TX 75056

Tel: 1-214-937-3199 or 1-888-298-5700

Email: complaints@orthofix.com

Therapeutic Goods Administration:

https://www.tga.gov.au

(Please click on "Consumers", then click on button "Report a problem or side effect" and then follow the instructions reported in "I want to report a problem with a medical device (adverse event)" section.)